Invivo Therapeutics Holdings Corp  

(Public, NASDAQ:NVIV)   Watch this stock  
Find more results for OTC:NVIV
+1.04 (12.64%)
Nov 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.33 - 9.42
52 week 3.51 - 19.68
Open 8.33
Vol / Avg. 202,742.00/204,041.00
Mkt cap 225.15M
P/E     -
Div/yield     -
EPS -1.43
Shares 27.36M
Beta 1.26
Inst. own 26%
Nov 4, 2015
Q3 2015 InVivo Therapeutics Holdings Corp Earnings Release
Sep 10, 2015
InVivo Therapeutics Holdings Corp at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -36.13% -108.59%
Return on average equity -57.18% -195.09%
Employees 31 -
CDP Score - -


1 Kendall Sq Fl 4
CAMBRIDGE, MA 02139-1562
United States - Map
+1-617-8635524 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The Company's technologies incorporate intellectual property licensed under an exclusive around the world license from Boston Children's Hospital (BCH) and the Massachusetts Institute of Technology (MIT), and intellectual property that has been developed internally, including in collaboration with its advisors and partners. The Company intends to leverage its platform technology to develop the Neuro-Spinal Scaffold, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury (SCI). The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.

Officers and directors

Mark D. Perrin Chairman of the Board, Chief Executive Officer
Age: 58
Bio & Compensation  - Reuters
Steven F. McAllister Chief Financial Officer
Age: 56
Bio & Compensation  - Reuters
Tamara L. Joseph J.D. Senior Vice President, Chief Compliance Officer, General Counsel
Age: 52
Bio & Compensation  - Reuters
Thomas R. Ulich M.D. Chief Scientific Officer
Age: 61
Bio & Compensation  - Reuters
Lorianne K. Masuoka M.D. Chief Medical Officer
Age: 53
Bio & Compensation  - Reuters
Ann Merrifield Lead Independent Director
Age: 64
Bio & Compensation  - Reuters
Kenneth A. Di Pietro Independent Director
Age: 56
Bio & Compensation  - Reuters
Daniel R. Marshak Ph.D. Independent Director
Age: 58
Bio & Compensation  - Reuters
John A. McCarthy Jr. Independent Director
Age: 52
Bio & Compensation  - Reuters
Richard J Roberts Ph.D. Independent Director
Age: 71
Bio & Compensation  - Reuters